Mackenzie Financial Corp Buys 1,224 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Mackenzie Financial Corp grew its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 96,855 shares of the company’s stock after acquiring an additional 1,224 shares during the period. Mackenzie Financial Corp owned about 0.10% of Neurocrine Biosciences worth $12,762,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Acadian Asset Management LLC purchased a new position in shares of Neurocrine Biosciences in the first quarter worth about $27,000. Headinvest LLC purchased a new position in Neurocrine Biosciences in the 3rd quarter valued at approximately $28,000. KB Financial Partners LLC bought a new stake in Neurocrine Biosciences during the 1st quarter valued at $32,000. BluePath Capital Management LLC bought a new stake in Neurocrine Biosciences during the 3rd quarter valued at $35,000. Finally, Covestor Ltd boosted its holdings in shares of Neurocrine Biosciences by 431.0% in the first quarter. Covestor Ltd now owns 377 shares of the company’s stock worth $35,000 after acquiring an additional 306 shares during the period. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Insider Buying and Selling

In related news, insider Darin Lippoldt sold 10,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $139.86, for a total transaction of $1,398,600.00. Following the sale, the insider now directly owns 35,882 shares in the company, valued at $5,018,456.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Darin Lippoldt sold 10,000 shares of the business’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $139.86, for a total transaction of $1,398,600.00. Following the sale, the insider now owns 35,882 shares of the company’s stock, valued at $5,018,456.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ingrid Delaet sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $145.06, for a total transaction of $725,300.00. Following the transaction, the insider now directly owns 7,507 shares of the company’s stock, valued at approximately $1,088,965.42. The disclosure for this sale can be found here. Insiders sold 196,994 shares of company stock valued at $27,205,009 over the last quarter. 4.40% of the stock is owned by company insiders.

Neurocrine Biosciences Price Performance

Shares of NBIX opened at $132.00 on Friday. The firm has a market cap of $13.14 billion, a P/E ratio of 54.55 and a beta of 0.25. Neurocrine Biosciences, Inc. has a 1 year low of $89.04 and a 1 year high of $148.37. The stock has a 50 day simple moving average of $136.15 and a two-hundred day simple moving average of $126.99.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.13 by $0.31. The business had revenue of $515.20 million during the quarter, compared to analyst estimates of $518.52 million. Neurocrine Biosciences had a net margin of 13.23% and a return on equity of 12.85%. The company’s revenue was up 25.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.88 earnings per share. On average, equities analysts anticipate that Neurocrine Biosciences, Inc. will post 4.84 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently issued reports on NBIX. Wells Fargo & Company boosted their price objective on Neurocrine Biosciences from $127.00 to $140.00 and gave the company an “equal weight” rating in a research note on Thursday, February 8th. Wedbush reiterated an “outperform” rating and set a $147.00 price target on shares of Neurocrine Biosciences in a research report on Wednesday. Barclays increased their price target on shares of Neurocrine Biosciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Tuesday, January 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday, April 10th. Finally, Mizuho upped their target price on shares of Neurocrine Biosciences from $116.00 to $140.00 and gave the stock a “neutral” rating in a report on Thursday, February 8th. Six analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $139.67.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.